Oh H, Yoon EL, Jun DW, et al. - In this retrospective study, researchers contrasted the incidence of hepatocellular carcinoma (HCC) development between patients treated with oral entecavir or tenofovir and followed for the same time periods. Data were obtained from 1,560 treatment-naïve patients with chronic HBV infection who were first treated with entecavir (n = 753) or tenofovir (n = 807) from 2011 through 2015 at nine academic hospitals in Korea. During the follow-up period, 34 patients in the entecavir group and 45 patients in the tenofovir group developed HCC. The incidence of HCC was not significantly different for patients treated with entecavir and tenofovir over the same observation period.